Imugene thrilled as first patients dosed in VAXINIA MAST combination study | News Direct

Imugene thrilled as first patients dosed in VAXINIA MAST combination study

Imugene Ltd
News release by Imugene Ltd

facebook icon linkedin icon twitter icon pinterest icon email icon Melbourne, Victoria | March 03, 2023 11:40 AM Eastern Standard Time

Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intravenous and intratumoral (IT) cohorts in combination with Pembrolizumab. Overall the study aims to recruit up to 100 patients across around 10 trial sites in the United States and Australia.

 

 

Contact Details

 

Proactive Investors

 

Jonathan Jackson

 

+61 413 713 744

 

Jonathan@proactiveinvestors.com

project media

Tags

Imugene LimitedcancerbiotechAsxproactiveAustraliaproactiveInvestors